Jim Simons Graphite Bio, Inc. Transaction History

Renaissance Technologies LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$2.24 - $2.66 $709,533 - $842,570	316,756 Added 119.8%	581,156 $1.52 Million
Q3 2023 Nov 14, 2023	BUY	$2.18 - $2.77 $44,254 - $56,231	20,300 Added 8.32%	264,400 $656,000
Q2 2023 Aug 11, 2023	BUY	$2.47 - $3.38 $39,273 - $53,742	15,900 Added 6.97%	244,100 $635,000
Q1 2023 May 12, 2023	SELL	$1.85 - $3.21 $188,093 - $326,367	-101,672 Reduced 30.82%	228,200 $559,000
Q4 2022 Feb 13, 2023	SELL	$2.82 - $3.59 $541,713 - $689,628	-192,097 Reduced 36.8%	329,872 $1.1 Million

Q3 2022 Nov 14, 2022	SELL	$2.82 - $4.24 $748,233 - $1.13 Million	-265,331 Reduced 33.7%	521,969 $1.66 Million
Q2 2022 Aug 12, 2022	BUY	$2.14 - $5.23 $1.68 Million - $4.12 Million	787,300 New	787,300 $2.17 Million

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.